Last reviewed · How we verify
NeoVax
At a glance
| Generic name | NeoVax |
|---|---|
| Also known as | neoantigen vaccine, Neoantigen vaccine, Synthetic long peptides plus poly-ICLC |
| Sponsor | Patrick Ott, MD, PhD |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- NeoVax + CDX-301 and Nivolumab or Pembrolizumab in Melanoma (PHASE1)
- Personalized Neoantigen Cancer Vaccine + Pembrolizumab After Rituximab for Follicular Lymphoma (PHASE1)
- Personalized NeoAntigen Cancer Vaccine w RT Plus Pembrolizumab for Patients With Newly Diagnosed GBM (PHASE1)
- NeoVax Plus Ipilimumab in Renal Cell Carcinoma (PHASE1)
- Neoantigen Vaccine Plus Locally Administered Ipilimumab and Systemic Nivolumab in Advanced Melanoma (PHASE1)
- A Phase I Study With a Personalized NeoAntigen Cancer Vaccine in Melanoma (PHASE1)
- NeoVax With Nivolumab in Patients With Ovarian Cancer (PHASE1)
- A Personalized Neoantigen Cancer Vaccine in Treatment Naïve, Asymptomatic Patients With IGHV Unmutated CLL. (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- NeoVax CI brief — competitive landscape report
- NeoVax updates RSS · CI watch RSS
- Patrick Ott, MD, PhD portfolio CI